Officers and directors of the nation's smallest and youngest biotech companies can look up their stock quotes once again.
Stocks in the sector were in such rapid freefall a few months ago
that a glance at the stock price chart became too painful to bear.
How painful was the sell-off?
I counted 30 biotech stocks that shed at least 40% of their value in
the past three months, with half of them plunging by more than 50%. (more)
Please share this article
No comments:
Post a Comment